Vaccine INFANRIX HEXA – (1,890) in Karachi at Dr. Essa Lab

Vaccine INFANRIX HEXA – (1,890) at Dr. Essa Lab

The Vaccine INFANRIX HEXA – (1,890) at Dr. Essa Lab represents a cornerstone of modern pediatric preventative medicine. This advanced hexavalent combination vaccine is designed to provide comprehensive active immunization for infants and toddlers against six highly infectious and potentially life-threatening diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio), and invasive diseases caused by Haemophilus influenzae type b (Hib). By combining these crucial immunizations into a single, highly engineered formulation, the vaccine significantly reduces the number of injections a child must receive during their critical first year of life. This not only minimizes physical discomfort and emotional distress for the infant but also simplifies the immunization schedule for parents and healthcare providers, leading to higher compliance rates and broader community immunity.

The technology behind the Vaccine INFANRIX HEXA – (1,890) is highly sophisticated. It utilizes non-infectious, purified components of the target pathogens to stimulate the child’s immune system safely. Specifically, it contains diphtheria and tetanus toxoids (detoxified bacterial toxins), acellular pertussis antigens (purified proteins of Bordetella pertussis, which carry a lower risk of side effects compared to whole-cell vaccines), recombinant hepatitis B surface antigen (produced via yeast cells), inactivated poliovirus strains (types 1, 2, and 3), and the capsular polysaccharide of Hib chemically conjugated to a tetanus toxoid carrier protein to enhance immunogenicity in young infants. When administered, this combination prompts the infant’s immune system to produce specific antibodies against each of these six pathogens, establishing long-term immunological memory without exposing the child to the risks of the actual diseases.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure a smooth, safe, and stress-free vaccination experience for both the infant and the parents. When scheduling the Vaccine INFANRIX HEXA – (1,890) at Dr. Essa Lab, please observe the following guidelines:

• Assess General Health: Ensure your child is in good general health on the day of vaccination. If your child has a high fever or an acute moderate-to-severe illness, consult your pediatrician, as the vaccination may need to be temporarily postponed. Mild illnesses, such as a common cold or a low-grade fever, are generally not contraindications.
• Bring Immunization Records: Always bring your child’s official vaccination card or record book to Dr. Essa Lab. Accurate documentation is vital for maintaining the correct immunization schedule.
• Dress Comfortably: Dress your infant in loose-fitting, comfortable clothing that allows easy access to the thigh. The vaccine is administered intramuscularly into the anterolateral aspect of the thigh (vastus lateralis muscle).
• Feeding Guidelines: Feed your baby shortly before the appointment to keep them calm, but avoid overfeeding immediately prior to the injection to minimize the risk of spitting up due to crying.
• Disclose Medical History: Inform the healthcare professional of any known allergies, bleeding disorders, previous adverse reactions to vaccines, or if the child is receiving any immunosuppressive therapy.

During the Procedure

The administration of the Vaccine INFANRIX HEXA – (1,890) at Dr. Essa Lab is performed by highly trained, compassionate pediatric nurses or clinical staff who prioritize patient safety and comfort. The procedure follows strict clinical protocols:

• Patient Positioning: The parent or guardian will be asked to hold the infant securely on their lap in a comforting position that stabilizes the child’s legs, preventing sudden movements during the injection.
• Aseptic Technique: The clinical professional will verify the vaccine details, check the expiration date, and prepare the injection. The skin over the anterolateral thigh is thoroughly cleansed with an antiseptic swab and allowed to dry.
• Injection Administration: The vaccine is delivered via a precise intramuscular injection. The nurse gently pinches the muscle and inserts the sterile, single-use needle at a 90-degree angle to ensure the vaccine is deposited deep into the muscle tissue, which optimizes absorption and minimizes local irritation.
• Duration and Immediate Care: The actual injection takes only a few seconds. Immediately afterward, gentle pressure is applied to the site with a sterile cotton ball. A small adhesive bandage may be applied.
• Post-Vaccination Observation: Parents are advised to remain in the waiting area at Dr. Essa Lab for approximately 15 to 30 minutes post-injection. This standard safety precaution allows the clinical team to monitor the infant for any rare, immediate allergic reactions.

When is a Vaccine INFANRIX HEXA – (1,890) Performed?

Primary Pediatric Immunization Schedule

The Vaccine INFANRIX HEXA – (1,890) is primarily administered during infancy as part of the routine primary immunization course. Pediatric guidelines, including those from the World Health Organization (WHO) and national immunization programs, typically recommend administering this hexavalent vaccine at specific intervals, such as at 2, 4, and 6 months of age, or at 2, 3, and 4 months. Adhering strictly to this schedule is vital because infants are highly vulnerable to infectious diseases as maternal antibodies naturally decline. Timely administration ensures the early development of protective antibody levels, safeguarding the infant during their most vulnerable developmental stages.

Prevention of Diphtheria, Tetanus, and Pertussis

Physicians prescribe this vaccine to prevent three severe bacterial infections. Diphtheria can cause a thick membrane to form in the throat, leading to severe breathing difficulties, heart failure, and paralysis. Tetanus, or lockjaw, is a painful and often fatal nervous system disorder caused by bacterial toxins entering wounds, leading to severe muscle spasms. Pertussis (whooping cough) is highly contagious and causes intense, uncontrollable coughing fits that can make it difficult for infants to breathe, eat, or drink, often leading to severe complications like pneumonia, brain damage, or death. The acellular pertussis component in this vaccine provides robust protection with a significantly reduced risk of post-vaccination fever compared to older whole-cell vaccines.

Protection Against Poliomyelitis (Polio)

Poliomyelitis is a highly infectious viral disease that attacks the nervous system and can cause irreversible paralysis or death within hours. In Pakistan, where polio eradication efforts remain a critical public health priority, ensuring complete immunization is of paramount importance. The Vaccine INFANRIX HEXA – (1,890) contains inactivated poliovirus (IPV), which is highly effective and completely eliminates the risk of vaccine-associated paralytic poliomyelitis (VAPP). Clinicians utilize this vaccine to build systemic immunity against poliovirus types 1, 2, and 3, protecting both the individual child and contributing to the broader eradication of the virus.

Immunization Against Hepatitis B and Hib

Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease, potentially leading to cirrhosis or liver cancer later in life. Infants are at a high risk of developing chronic infections if exposed early. Haemophilus influenzae type b (Hib) is a bacterium responsible for severe, invasive infections in children under five, including bacterial meningitis (infection of the brain membranes), epiglottitis (severe swelling of the windpipe), pneumonia, and septicemia. The vaccine stimulates the production of protective antibodies against both pathogens, preventing these devastating, long-term health complications.

Reducing Injection Burden for Infants

One of the primary clinical indications for choosing the Vaccine INFANRIX HEXA – (1,890) is the reduction of injection-related trauma and stress. Historically, protecting an infant against these six diseases required multiple separate injections during a single visit. This combination vaccine reduces the number of injections from up to twelve down to just three or four during the primary series. Pediatricians recommend this hexavalent formulation to improve the overall vaccination experience, reduce parental anxiety, minimize clinic visit times, and ensure that infants receive all necessary immunizations on time without delay.

What Does a Vaccine INFANRIX HEXA – (1,890) Detect?

While the Vaccine INFANRIX HEXA – (1,890) is a preventative immunization rather than a diagnostic test, its clinical administration involves monitoring several key physiological parameters, immunological markers, and safety indicators to ensure successful immunization and patient safety. Clinicians and pediatricians evaluate the following aspects associated with the vaccine:

• Diphtheria Toxoid Immunogenicity: The stimulation of specific IgG antibodies against Corynebacterium diphtheriae toxin.
• Tetanus Toxoid Immunogenicity: The production of protective IgG antibodies against Clostridium tetani neurotoxin.
• Pertussis Toxoid (PT) Antibody Response: The generation of antibodies targeting the primary toxin produced by Bordetella pertussis.
• Filamentous Haemagglutinin (FHA) Antibodies: The development of antibodies against the bacterial attachment protein of pertussis.
• Pertactin (PRN) Antibody Levels: The immune response to the outer membrane protein of Bordetella pertussis, crucial for adhesion.
• Hepatitis B Surface Antibody (anti-HBs) Titers: The quantitative level of antibodies against the Hepatitis B virus surface antigen.
• Poliovirus Type 1 Neutralizing Antibodies: The presence of neutralizing antibodies against the Mahoney poliovirus strain.
• Poliovirus Type 2 Neutralizing Antibodies: The presence of neutralizing antibodies against the MEF-1 poliovirus strain.
• Poliovirus Type 3 Neutralizing Antibodies: The presence of neutralizing antibodies against the Saukett poliovirus strain.
• Anti-PRP Antibody Response: The production of antibodies against the polyribosylribitol phosphate capsular polysaccharide of Haemophilus influenzae type b.
• Prevention of Systemic Diphtheria: Clinical absence of pseudomembrane formation and systemic toxemia.
• Prevention of Tetanus Spasms: Clinical absence of generalized muscular rigidity and lockjaw.
• Prevention of Whooping Cough Paroxysms: Clinical absence of severe coughing fits accompanied by the classic inspiratory “whoop”.
• Prevention of Chronic Hepatitis B Carrier State: Long-term protection against persistent hepatic viral replication.
• Prevention of Paralytic Poliomyelitis: Clinical absence of acute flaccid paralysis.
• Prevention of Hib Meningitis: Prevention of bacterial invasion into the central nervous system.
• Prevention of Hib Epiglottitis: Prevention of acute, life-threatening airway obstruction.
• Prevention of Hib Osteomyelitis and Arthritis: Protection against localized bacterial bone and joint infections.
• Injection Site Erythema: Monitoring for localized redness as a normal inflammatory response.
• Injection Site Induration: Assessment of localized swelling or hardness at the injection site.
• Post-Vaccination Pyrexia: Monitoring the infant’s body temperature for transient, low-grade fever.
• Systemic Behavioral Changes: Observing for mild, transient irritability, restlessness, or unusual crying.
• Appetite Assessment: Monitoring for temporary loss of appetite or feeding difficulties post-vaccination.
• Gastrointestinal Tolerance: Monitoring for mild, transient diarrhea or vomiting.
• Hypersensitivity Reactions: Screening for immediate allergic reactions, such as urticaria or angioedema.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, the administration of the Vaccine INFANRIX HEXA – (1,890) is documented immediately to ensure accurate medical records. Upon successful administration of the vaccine, the clinical staff will instantly update your child’s physical vaccination card with the date, vaccine batch number, manufacturer details, and the signature of the administering professional. This physical record is essential for school admissions, travel, and future medical consultations.

In addition to the physical card, Dr. Essa Lab leverages modern digital healthcare solutions. The details of the vaccination are uploaded to the secure online patient portal and mobile application. Parents can access these digital records at any time, allowing for convenient tracking of their child’s immunization history and upcoming vaccine schedules. If any serological testing is performed in conjunction with clinical evaluations, those laboratory reports are typically available online within 24 to 48 hours, ensuring seamless access to your family’s healthcare data.

Vaccine INFANRIX HEXA – (1,890) Findings Overview

The following table outlines the key parameters, expected normal responses, and potential abnormal findings associated with the administration and monitoring of the Vaccine INFANRIX HEXA – (1,890):

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Diphtheria Toxoid Antibody Level	Protective antibody titers (≥ 0.1 IU/ml) indicating active immunity.	Sub-protective titers (< 0.1 IU/ml) requiring booster doses.
Tetanus Toxoid Antibody Level	Protective antibody titers (≥ 0.1 IU/ml) ensuring neuromuscular protection.	Sub-protective titers (< 0.1 IU/ml) indicating inadequate immunity.
Pertussis Antibody Response	Significant seroconversion and high titers of antibodies to PT, FHA, and PRN.	Inadequate antibody response, leaving the child vulnerable to whooping cough.
Hepatitis B Surface Antibody (anti-HBs)	Protective antibody levels (≥ 10 mIU/ml) indicating long-term liver protection.	Non-protective levels (< 10 mIU/ml) requiring clinical evaluation.
Poliovirus Neutralizing Antibodies	High neutralizing antibody titers against poliovirus types 1, 2, and 3.	Inadequate neutralizing titers, failing to protect against paralytic polio.
Hib (PRP) Antibody Level	Antibody titers ≥ 0.15 mcg/ml (short-term) or ≥ 1.0 mcg/ml (long-term protection).	Sub-therapeutic antibody levels, increasing risk of invasive Hib infections.
Local Injection Site Reaction	No reaction, or mild, transient redness, swelling, and tenderness resolving in 2-3 days.	Severe local reactions, extensive swelling of the injected limb, or sterile abscess.
Systemic Post-Vaccine Response	Normal temperature, mild transient irritability, or low-grade fever (< 38.5°C).	High-grade fever (> 40°C), persistent crying lasting ≥ 3 hours, or febrile convulsions.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Vaccine INFANRIX HEXA – (1,890)?

• Experienced healthcare professionals: Our clinical staff and pediatric nurses are highly trained in administering vaccines gently and safely to infants.
• Patient-focused care: We prioritize the comfort and emotional well-being of both the child and parents during the vaccination process.
• Quality diagnostic services: Dr. Essa Lab maintains strict cold chain protocols to preserve the potency and efficacy of all vaccines.
• Professional reporting: We provide immediate physical and digital updates to your child’s immunization record for seamless tracking.
• Modern diagnostic approach: Our facilities utilize state-of-the-art medical equipment and follow international clinical guidelines.
• Comfortable environment: Our clinics offer clean, sterile, and child-friendly waiting and vaccination areas.
• Convenient location: With numerous branches across Karachi and other major cities, accessing quality healthcare is highly convenient.
• Commitment to accurate diagnosis: We are dedicated to providing reliable, evidence-based healthcare services to protect your family’s health.